semaglutide april 22 2025 ADA 2025: Oral Demonstrates Cardiovascular Benefits in SOUL Trial semaglutide april 22 2025 Out

The FDA does not verify the safety or effectiveness of compounded drugs

Here are the main safety concerns: Dosing errors: The FDA has reported multiple dosing errors with compounded semaglutide, particularly when its dispensed in multi-dose vials

Excess gas may be linked to stomach problems like GERD (gastroesophageal reflux disease) and IBS (irritable bowel syndrome)

It can also break down muscle tissue if protein intake is insufficient

Obese and diabetic non-human primates 43,44 could be very helpful animal models to analyse the pharmacology of MEDI4166 for both glucose control and LDL-C reduction and might provide additional insights to precisely predict its efficacy in humans

Clinical sequelae include CVD, metabolic disorders, and neurocognitive disorders as dysbiosis is associated with inflammaging, the chronic low-grade inflammation that accelerates atherosclerosis, insulin resistance and cognitive decline